Oral Isobutyramide Therapy in Patients with Thalassemia Intermedia: Results of a Phase II Open Study

Author： Domenica Cappellini M.   Graziadei G.   Ciceri L.   Comino A.   Bianchi P.   Porcella A.   Fiorelli G.  

Publisher： Academic Press

ISSN： 1079-9796

Source： Blood Cells, Molecules, and Diseases, Vol.26, Iss.1, 2000-02, pp. : 105-111

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Comparative study of hypogonadism in beta-thalassemia intermedia patients with and without hydroxyurea

By Karimi Mehran   Zekavat Omid R.   Haghpanah Sezaneh   Javad Parvin   Karamizadeh Zohreh  

Hematology, Vol. 17, Iss. 2, 2012-03 ,pp. : 122-124

Maney Publishing

Access to resources Recommend Favorite

Iron-chelation therapy with oral chelators in patients with thalassemia major

By Uygun Vedat  

Hematology, Vol. 18, Iss. 1, 2013-01 ,pp. : 50-55

Maney Publishing

Access to resources Recommend Favorite

The expanding spectrum of thalassemia intermedia

By Panigrahi Inusha   Marwaha Ram K.   Kulkarni Ketan  

Hematology, Vol. 14, Iss. 6, 2009-12 ,pp. : 311-314

Maney Publishing

Access to resources Recommend Favorite

Phase II study on the combination of irinotecan plus cisplatin as a secondline therapy in patients with advanced or recurrent gastric cancer

By                    

Molecular and Clinical Oncology, Vol. 1, Iss. 4, 2013-01 ,pp. : 749-752

Spandidos Publications

Access to resources Recommend Favorite

Immune parameters of patients treated with laquinimod, a novel oral therapy for the treatment of multiple sclerosis: results from a double‐blind placebo‐controlled study

By  

Immunity, Inflammation And Disease, Vol. 3, Iss. 2, 2015-06 ,pp. : 45-55

John Wiley & Sons Inc

Access to resources Recommend Favorite